+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Why not to interfere with LDL-cholesterol freefall and why not to talk badly about statins



Why not to interfere with LDL-cholesterol freefall and why not to talk badly about statins



Vnitrni Lekarstvi 64(12): 1169-1175



Thanks to new drugs and treatments it is now possible, and therefore also advisable, to achieve very low LDL-cholesterol levels. This is primarily the inhibition of the proproteinconvertase subtilisin kexin 9 and LDL apheresis. Despite these new procedures, they remain the main antagonist of atherosclerosis and atherogenic dyslipidemia of statins. Statins are the basis of treatment always. If they are not enough or if they actually cause uncontrollable difficulties, they can be supplemented or replaced by other medications or treatments that reduce values of LDL-cholesterol. Often, however, their full potential is not fully exploited, and there are still completely unjustified concerns about their frequent and dangerous undesirable effects. We did our best to discuss this topic in more detail in this article. Key words: aggressive treatment - LDL-cholesterol - statins.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 066446368

Download citation: RISBibTeXText

PMID: 30704253


Related references

Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?. Urologic Nursing 27(2): 166-168, 2007

Pre-Treatment with Statins for Coronary Intervention: Pleiotropy of Statins or Effect of LDL-cholesterol Reduction?. Korean Circulation Journal 46(4): 468-471, 2016

Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?. Harvard Heart Letter 14(6): 5-5, 2004

Underachievement of low-density lipoprotein cholesterol goal in patients on statins in clinical practice Are we using low doses of statins too often?. Journal of the American College of Cardiology 43(5 Supplement A): 250A, March 3, 2004

Statins redux: A re-assessment of how statins lower plasma cholesterol. World Journal of Diabetes 8(6): 230-234, 2017

Beyond statins. New drugs can work with, or in place of, cholesterol-lowering statins. Harvard Heart Letter 13(6): 3-3, 2003

LIFESTAT - Living with statins: An interdisciplinary project on the use of statins as a cholesterol-lowering treatment and for cardiovascular risk reduction. Scandinavian Journal of Public Health 44(5): 534-539, 2017

Beyond statins: assessing the alternatives. Some people can't tolerate statins, and others need additional medications to achieve healthy cholesterol levels. Harvard Heart Letter 25(3): 6-6, 2015

The role of fat tissue in the cholesterol lowering and the pleiotropic effects of statins--statins activate the generation of metabolically more capable adipocytes. Medical Hypotheses 64(1): 69-73, 2004

Statins, super-statins and cholesterol absorption inhibitors. Idrugs 6(5): 458-463, 2003

Not all statins interfere with clopidogrel during antiplatelet therapy. European Journal of Clinical Investigation 35(8): 476-481, 2005

Statins interfere with the expression of the profibrotic factor CTGF. Kidney & Blood Pressure Research 24(4-6): 270, 2001

Do statins really interfere with clopidogrel-induced platelet function?. European Heart Journal 25(5): 448; Author Reply 448-9, 2004

Cyclosporine does not interfere in total and high-density lipoprotein cholesterol measurement with use of enzymatic cholesterol assays. Clinical Chemistry 35(11): 2251-2252, 1989

Do statins interfere with physical activity in the treatment of metabolic syndrome?. Nutrition, Metabolism, and Cardiovascular Diseases 18(3): E9, 2007